Corient Private Wealth
ENTA icon

Corient Private Wealth’s Enanta Pharmaceuticals ENTA Stock Holding History

Corient Private Wealth’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,874
Closed -$71.1K – 2468
2025
Q1 		$71.1K Buy
+12,874
New +$79.5K ﹤0.01% 2204

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Private Wealth's ENTA Position: Q2 2025 in Review

Corient Private Wealth sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 12,874 shares — an estimated $71.1K sold.

Corient Private Wealth first reported a position in ENTA in Q1 2025 and held it in 1 quarter. The position peaked at $71.1K in Q1 2025. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

  • Corient Private Wealth reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corient Private Wealth sold 12,874 Enanta Pharmaceuticals shares in Q2 2025, an estimated $71.1K.
  • Corient Private Wealth first reported a position in Enanta Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Corient Private Wealth's Enanta Pharmaceuticals position peaked at $71.1K in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on Corient Private Wealth's 13F filing for Q2 2025, filed 15 Aug 2025.